Actively Recruiting
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
Led by Fifth Affiliated Hospital, Sun Yat-Sen University · Updated on 2023-09-29
1200
Participants Needed
1
Research Sites
282 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Quantitative MRI scanning parameters such as T1 mapping, T2 mapping, T1ρ, and elastography are used, combined with clinical and laboratory indicators, to predict the risk of liver cancer in patients with cirrhosis.
CONDITIONS
Official Title
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged over 18 years old
- Liver function Child-Pugh classification A or B
- Patients with chronic liver disease meeting high-risk liver cancer criteria in the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)"
- Availability of Gd-EOB-DTPA enhanced MRI scans including T1 mapping, T2 mapping, T2* mapping, and T1c1 sequences
- Availability of 5-year follow-up data
You will not qualify if you...
- Unable to undergo MRI scanning due to claustrophobia, abnormal kidney function, or other reasons
- History of prior liver surgery
- Presence of major diseases such as heart failure or tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yaqin, Zhang
Zhuhai, Guangdong, China
Actively Recruiting
Research Team
Y
Yaqin Zhang, MD, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here